Evaluating the use of glucagon‐like peptide‐1 receptor agonists in a matched cohort of kidney and liver transplant recipients
Mary Grace Fitzmaurice, Deepak Venkat, Milagros Samaniego(Henry Ford Health System), Arin Jantz, Nadeen Khoury, A. Poparad-Stezar, Humberto C. González(Wayne State University)
Cited by 2
Related Papers
KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update
|American Journal of Kidney Diseases|2015|1.3k
Plasmapheresis, CMV Hyperimmune Globulin, and Anti-CD20 Allow ABO-Incompatible Renal Transplantation Without Splenectomy
|American Journal of Transplantation|2004|283
Adverse Outcomes of Tacrolimus Withdrawal in Immune–Quiescent Kidney Transplant Recipients
|Journal of the American Society of Nephrology|2015|193
Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study
|The Lancet|2016|181
Clinical characteristics and outcomes of COVID-19 in solid organ transplant recipients: A cohort study
|American Journal of Transplantation|2020|134